Targeting the Cause of Obstructive Hypertrophic Cardiomyopathy

The first drug targeting the underlying pathophysiology of obstructive hypertrophic cardiomyopathy (OHCM) gained FDA approval for patients with symptomatic New York Heart Association (NYHA) class II and III disease.